Review The role of Sphingolipids in myelination and myelin stability and their involvement in childhood and adult demyelinating disorders, 2021, Giussani+

Discussion in 'Other health news and research' started by SNT Gatchaman, Dec 11, 2023.

  1. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,003
    Location:
    Aotearoa New Zealand
    The role of Sphingolipids in myelination and myelin stability and their involvement in childhood and adult demyelinating disorders
    Paola Giussani; Alessandro Prinetti; Cristina Tringali

    Multiple sclerosis (MS) represents the most common demyelinating disease affecting the central nervous system (CNS) in adults as well as in children. Furthermore, in children, in addition to acquired diseases such as MS, genetically inherited diseases significantly contribute to the incidence of demyelinating disorders.

    Some genetic defects lead to sphingolipid alterations that are able to elicit neurological symptoms. Sphingolipids are essential for brain development, and their aberrant functionality may thus contribute to demyelinating diseases such as MS. In particular, sphingolipidoses caused by deficits of sphingolipid-metabolizing enzymes, are often associated with demyelination.

    Sphingolipids are not only structural molecules but also bioactive molecules involved in the regulation of cellular events such as development of the nervous system, myelination and maintenance of myelin stability. Changes in the sphingolipid metabolism deeply affect plasma membrane organization. Thus, changes in myelin sphingolipid composition might crucially contribute to the phenotype of diseases characterized by demyelinalization.

    Here, we review key features of several sphingolipids such as ceramide/dihydroceramide, sphingosine/dihydrosphingosine, glucosylceramide and, galactosylceramide which act in myelin formation during rat brain development and in human brain demyelination during the pathogenesis of MS, suggesting that this knowledge could be useful in identifying targets for possible therapies.

    Link | PDF (Journal of Neurochemistry)
     
  2. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,003
    Location:
    Aotearoa New Zealand
     
    alktipping likes this.
  3. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,003
    Location:
    Aotearoa New Zealand
    In Phenotypic characteristics of peripheral immune cells of Myalgic encephalomyelitis/chronic fatigue syndrome via transmission electron microscopy: A pilot study (2022, PLOS ONE) —

    Note that SSRIs directly downregulate acid sphingomyelinase. See Mechanisms of action of fluvoxamine for COVID-19: a historical review (2022, Nature Molecular Psychiatry) —

    Note also that activated platelets release S1P. See Activated platelets release sphingosine 1-phosphate and induce hypersensitivity to noxious heat stimuli in vivo (2015, Frontiers in Neuroscience)
     
    Last edited: Dec 11, 2023
    Trish and alktipping like this.
  4. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,003
    Location:
    Aotearoa New Zealand
    See also —

    Myelin lipid metabolism and its role in myelination and myelin maintenance (2022, The Innovation)

    Abnormal brain diffusivity in participants with persistent neuropsychiatric symptoms after COVID-19 (2023, NeuroImmune Pharmacology and Therapeutics)

    MRI with generalized diffusion encoding reveals damaged white matter in patients previously hospitalized for COVID-19 and with persisting symptoms at follow-up (2023, Brain Communications)

    (Speculatively: I wouldn't be completely surprised if DecodeME ended up pinging SMPD1 — and perhaps there's more chance given the protocol to more easily include the severely affected.)
     
    Trish and alktipping like this.

Share This Page